logo
Radio vision: See through smoke and around corners

Radio vision: See through smoke and around corners

BBC News14-02-2025

If you want to find out whether your robot can see through smoke, well, you're going to need some smoke.But a University of Pennsylvania student got a shock when they began setting up a late night experiment to test such a robot.Shortly after flicking the switch on the smoke machine, a loud fire alarm went off. "The whole building got triggered," says Mingmin Zhao of the University of Pennsylvania, smiling. "My student called me. He was very surprised."The incident was a minor setback for the team developing a robot equipped with a innovative radio-based sensing system.Radio waves could allow robots or autonomous vehicles to see through thick smoke, intense rain – or even around corners. Such waves can even detect concealed weapons.But simulating visual imagery based on radio waves is an unusual approach for robots and autonomous vehicles. Much more established in those fields are regular optical cameras, light detection and ranging (Lidar), and other sensors.However, Prof Zhao and his students have developed a potentially powerful way for robots to see using radio waves.Of course radar, which uses radio waves, has been used for decades to track aircraft, ships and the weather. But the spinning array on Prof Zhao's robot throws radio waves in all directions. An on-board artificial intelligence (AI) system then builds a 3D view of the environment with this information."What we have been trying to do here is basically help robots obtain superhuman vision – to see in scenarios where human eyes or traditional visual sensors cannot," explains Prof Zhao.He suggests the technology could help a future search-and-rescue robot save people from a burning building.Subsequent tests of the bot used a clear plastic box full of smoke placed around the its spinning equipment, in order to avoid triggering any nearby fire alarms.
Although humans can't see them, radio waves are a form of light in the sense that they are part of the electromagnetic spectrum, which also includes X-rays and gamma rays. Only a small part the spectrum is classed as visible light.Being light, radio waves can reflect off surfaces and materials, though in a slightly different way to visible light. Prof Zhao and his colleagues have designed their robot so that it can sense these radio wave reflections.The crucial factor here is that radio waves are much longer than visible light waves meaning they are not blocked by tiny smoke particles.Prof Zhao says he has also been working on adapting the technology so that the robot can see part of the way round a corner. Think of it like a hall of mirrors, he suggests, just for radio waves rather than visible light."It's really very interesting work and quite impressive," says Friedemann Reinhard at the University of Rostock in Germany, who was not involved in the work. In 2017, Prof Reinhard and colleagues described how Wi-Fi signals could allow spies to see into private rooms.One slight limitation is that the spinning array cannot, by definition, see in all directions at once. Prof Reinhard says that a lot of data processing carried out by the system appears necessary to clean up the image that results from this spinning device.However, the robot sends out radio waves in the millimetre wave band (waves that are between one and ten millimetres long). This is the same technology used for some 5G installations."That's potentially very attractive, it's a very well understood, cheap technology," says Prof Reinhard. "I certainly would love to see a self-driving car driving only on radar."
But it is possible to avoid using spinning radio-emitting devices to get a full picture, says Fabio da Silva, founder and chief executive of US firm Wavsens, which is also developing radio-based sensing technology."We created an algorithm that allows you to sense the entire space instantaneously and continuously so we don't have to spin our antennas," he says.He describes the system as akin to echolocation, used by bats. It sends out radio waves and "listens" to how the waves come back, which reveals the shape of whatever they have hit.Some researchers have used radio waves to detect concealed weapons such as hidden handguns and knives.Radio waves can even "fingerprint" the details of a room. Then, if scanned again later, this would reveal whether any objects in the room have been moved.Last year, scientists in Germany proposed that countries use this method to scrutinise other countries' management of their nuclear weapons stockpiles. It would be one way of knowing whether someone had been moving the warheads around, for example.
Separately, Luana Olivieri at Loughborough University has explored using a different form of non-visible electromagnetic radiation, terahertz waves. These are shorter than radio waves but longer than visible light waves. "This wavelength is particularly unexplored," says Dr Olivieri.It is possible to see through objects and analyse materials using this form of radiation, she adds. Such a system could even, in theory, identify specific drugs by detecting their chemical structure.But while seeing through materials could help a rescue bot find a trapped person in some future disaster, it also has other applications. Police forces and militaries have access to radio-based technology that allows them to see through doors and walls, to some extent."Warfighting is definitely one market that it caters to. It can be used to find and kill someone," says Mr da Silva. He has exhibited Wavsens' technology to the US Department of Defense and the Israeli Ministry of Defense, he says.And yet these applications are not entirely surprising, suggests Prof Reinhard, who points out that a range of emerging technologies have, in principle, made it easier to detect and attack people."Maybe radar sounds scary – but drones and cheap cameras are the much more dangerous thing," he says.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cancer treatment turbocharges patients' own blood cells to kill solid tumours for first time
Cancer treatment turbocharges patients' own blood cells to kill solid tumours for first time

The Sun

time2 days ago

  • The Sun

Cancer treatment turbocharges patients' own blood cells to kill solid tumours for first time

A LIVING cancer drug has been proven to work against solid tumours for the first time. Immune-boosting CAR-T therapy removes a patient's white blood cells and engineers them into highly specialised cancer killers in a lab. 1 They are then injected back into the patient and let loose against the disease. It is currently only used for blood cell cancers like leukaemia but research by Peking University in China has found it can also work against tumours that form as lumps. In a study of 266 people with stomach cancer, patients who received the treatment survived an average of 7.9 months compared to 5.5 months without it. It took 3.3 months for their cancer to worsen, compared to 1.8 months without. Study author Dr Changsong Qi said the results showed a 'significant increase in progression-free survival and clinically meaningful increase in overall survival'. More than 90 per cent of cancers are solid tumours that grow as a physical mass, including the big four of bowel, breast, lung and prostate. The findings raise the hope that tens or even hundreds of thousands more patients will one day benefit from the pioneering approach using their own immune systems instead of harsh drugs. 'Groundbreaking milestone' Dr Carl June, of the University of Pennsylvania, is credited with inventing the therapy and commented: 'This is a groundbreaking milestone for the field of CAR-T therapies against solid tumours.' CAR-T therapy, full name chimeric antigen receptor T-cell therapy, is an advanced type of immunotherapy that turbocharges the body's own defences to fight off cancer. It is intended to be more accurate and cause less collateral damage and side effects by only attacking cancerous cells and not healthy ones. Sun Health Explainer: What is cancer? Young Sunderland fan Bradley Lowery took part in a major clinical trial of it in 2017 before dying from neuroblastoma aged six. It is currently available on the NHS in England for certain types of leukaemia and lymphoma. More than 650 forms of the treatment are now in development for solid cancers. Dr John Haanen, from the Netherlands Cancer Institute, said: 'There is clearly now evidence that this treatment can benefit patients with solid cancers. It is an important development.' The study was published in The Lancet and presented at the conference of the American Society for Clinical Oncology. Dr Catherine Elliott, of Cancer Research UK, said: 'This is an encouraging early sign and further trials will now be needed.'

Gilead's CAR-T cell therapy shows promise in deadly brain cancer
Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Reuters

time3 days ago

  • Reuters

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday. The study, presented at the American Society of Clinical Oncology meeting in Chicago and published in Nature Medicine, is the latest among several efforts testing next-generation chimeric antigen receptor T-cell or CAR-T treatments, a type of immunotherapy in which patients' immune cells are engineered to recognize and kill cancer cells. The work, from researchers at the University of Pennsylvania and Gilead's (GILD.O), opens new tab Kite cell therapy unit, tested a dual CAR-T treatment in an effort to overcome the defenses of glioblastoma, the most common brain tumor in adults. CAR-T therapy is already used to treat blood cancers including leukemia, lymphoma and multiple myeloma, and those treatments typically only take aim at one target on the tumor. But solid tumors such as glioblastoma tend to have multiple subpopulations of tumor cells, suggesting that treatments will need more than one target to succeed, said University of Pennsylvania researcher Dr. Stephen Bagley, who led the study. For the treatment, which is injected directly into spinal fluid, the team selected EGFR, which is found in 50% to 60% of all glioblastoma tumors, and a second target called interleukin-13 receptor alpha 2, found in an estimated 75% of glioblastoma tumors. Typically, advanced glioblastoma patients whose cancers return after initial treatment with surgery, radiation and chemotherapy live six to 10 months. Interim results of just six patients were published in March 2024 in Nature Medicine, opens new tab. The current study now includes 18 patients treated with the experimental therapy after their tumors returned following standard treatment. Of these, only 13 had a measurable tumor at the time the cells were introduced, and of those, eight, or 62%, had their tumors shrink, Bagley said. "That was pretty remarkable to us because historically for recurrent glioblastoma tumors, we usually don't see anything shrink them." Several patients lived 12 months or longer, and in one patient, the disease remained stable for 16 months. But so far, the benefit is largely temporary, with many patients relapsing two to three months later. Most patients experienced fevers and neurotoxicity such as lethargy or confusion for two or three days after the cells are injected, but the side effects were manageable, Bagley said. Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said she is encouraged by the 62% response. "What we didn't see that we wanted to in a majority of the patients was persistence," she said. Kite is working to develop a third target that will allow the drug to remain in the brain longer. "We will be putting that construct into the clinic sometime next year," she said. Meanwhile, the team wants to test the therapy in 12 patients with newly diagnosed disease. "We know patients in the frontline setting are going to be healthier," she said, and the hope is to see more persistent results. Demand for the trial has been great. Perettie estimates there are 10 times as many patients seeking enrollment for every open slot, and some doctors are referring patients from as far away as Hawaii. "Today, there's only one approved therapy outside of radiation, so for these patients, this is really exciting to see any kind of response," she said. Kite hopes to expand to three or four centers with its triple-target version of the product. "I think we're on the right track," Bagley said, adding that he believes there will be longer-lasting treatments in the next few years.

Immunotherapy trial helps cancer patients with tumours live 40% longer
Immunotherapy trial helps cancer patients with tumours live 40% longer

The Guardian

time3 days ago

  • The Guardian

Immunotherapy trial helps cancer patients with tumours live 40% longer

Cancer patients treated with a pioneering immunotherapy that genetically modifies their own cells to wipe out tumours live 40% longer, according to 'exciting' and 'groundbreaking' results from a world-first clinical trial. Car T-cell therapy is a new form of immunotherapy where a patient's own T-cells – a type of white blood cell – are tweaked in a lab to target and kill cancer cells. The designer cells are then infused back into their bloodstream to fight the disease. The therapy has already proved successful in treating blood cancers. Now results from the world's first randomised controlled trial of Car T-cell therapy in solid tumours suggest it could be transformative in the fight against these cancers too. Solid tumours represent about 90% of all cancers, including breast, lung and pancreatic cancer. In the trial hailed as a 'milestone' by experts, patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer treated with Car T-cell therapy lived on average approximately 40% longer than patients who received standard care. The results were published in The Lancet and presented at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco), in Chicago. Dr Carl June, a leading expert on Car T-cell therapy at the University of Pennsylvania, who was not involved with the trial, said: 'This is an exciting study showing the first positive results from a randomised trial testing Car T-cells for a solid cancer. 'The study shows that satri-cel Car T-cells provide significant benefits to advanced gastric cancer patients who have failed at least two prior lines of therapy. This represents a groundbreaking milestone for the field of Car-T therapies against solid tumours.' In the trial, more than 100 patients in China with advanced gastric or GEJ cancer were randomised to receive either Car T-cell therapy or one of the standard-of-care medications. Patients who received Car T-cell therapy lived an average of 7.9 months after randomisation, compared with 5.5 months through standard care. Patients receiving the designer immunotherapy also experienced 3.3 months without the cancer advancing compared with 1.8 months in the standard care group. The researchers, from Peking University Cancer Hospital & Institute in Beijing, said Car T-cell therapy 'showed a statistically significant improvement in progression-free survival and clinically meaningful improvement in overall survival'. The results suggest Car T-cell 'could represent a paradigm shift' in care, addressing a crucial unmet need for some patients, they added. Dr Jason Luke, an Asco expert and associate professor of medicine at the University of Pittsburgh, said the results were 'exciting'. He added: 'This is a very important 'plant the flag' publication that should rally the cancer research community to push forward toward improving the lives of patients [with] solid tumours.' A second study on Car T-cell, led by the University of Pennsylvania and due to be presented at Asco on Sunday, suggests the approach can also be used to treat brain tumours. Results from that trial are expected to show Car T-cell can shrink tumours in glioblastoma, an aggressive and fast-growing brain cancer, and help patients live much longer. Car – chimeric antigen receptor – T-cell therapy works by genetically engineering a patient's T-cells to recognise and destroy cancer cells. T-cells are a type of white blood cell that can recognise and destroy foreign cells, including cancer cells, but because cancer is able to evade immune detection, they often miss their mark. Car T-cells are engineered to make them better at detecting cancer cells. Oncologists in Chicago said they were increasingly optimistic that Car T-cell therapy could revolutionise treatment of solid tumours, after dramatic success with blood cancers. 'For solid cancers, there is clearly now not only an interest but evidence that this treatment can benefit patients, making this an important new development that should be shared,' said Dr John Haanen, of the Netherlands Cancer Institute, who will give a presentation on Car T-cell therapy at the Asco meeting. 'I think this [is] a new generation of treatment that wasn't there for medical oncologists before.' Dr Catherine Elliott, the director of research and partnerships at Cancer Research UK, said it was 'encouraging' to see early signs that Car T-cell therapy could help patients with solid tumours. The therapy will need to be trialled in larger numbers of patients before being rolled out widely, Elliott said, but 'could mark an important step forward for patients with limited treatment options'.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store